Historical perspectives on the current management of Parkinson's disease

Focus on Parkinson's Disease

Volumn 20, Issue 1, 2008, Pages 3-8

  Fahn, Stanley ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; APOMORPHINE; BELLADONNA ALKALOID; BENZATROPINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

AGE; ALZHEIMER DISEASE; ANXIETY; ARTICLE; AUTONOMIC DYSFUNCTION; AUTOPSY; BIOARTIFICIAL LIVER; BLURRED VISION; COGNITION; DEMENTIA; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DYSKINESIA; HEARING DISORDER; HUMAN; MENTAL DISEASE; MORBIDITY; MOTOR PERFORMANCE; NEUROIMAGING; PARKINSON DISEASE; PHYSIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PSYCHOPHARMACOLOGY; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY DYSFUNCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SOCIAL LIFE; URINE RETENTION; VISUAL HALLUCINATION;

EID: 79959712160     PISSN: 09242015     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Fahn S, Jankovic J. Principles and Practice of Movement Disorders. Philadelphia: Churchill Livingstone Elsevier; 2007.
2. Jankovic J. Pathophysiology and assessment of parkinsonian symptoms and signs. In: Pahwa R, Lyons K, Koller WC, editors. Handbook of Parkinson's Disease. New York: Taylor and Francis Group LLC; 2007. p. 79-104.
3. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368-76. (Pubitemid 351441488)
4. Piccini P, Brooks DJ. New developments of brain imaging for Parkinson's disease and related disorders. Mov Disord. 2006;21:2035-41. (Pubitemid 46140409)
5. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord. 2008 (in press).
6. Lees AJ. The magic of L-dopa. Focus on Parkinson's Disease. 2007;19:2-3.
7. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology. 2004;62:S56-63.
8. Friedman A. The use of levodopa in the treatment of Parkinson's disease. Focus on Parkinson's Disease. 2005;17:3-5. (Pubitemid 44072749)
9. Weintraub D, Comella CL, Horn S. Parkinson's disease - Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008;14:S40-8.
10. Chaudhuri KR, Healy DG, Schapira AH, et al. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5:235-45. (Pubitemid 43238347)
11. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006;13:1170-85. (Pubitemid 44581464)
12. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol. 2006;13:1186-202. (Pubitemid 44581465)
13. Suchowersky O, Reich S, Perlmutter J, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:968-75. (Pubitemid 44044778)
14. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-95. (Pubitemid 44044780)
15. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996-1002.
16. Suchowersky O, Gronseth G, Perlmutter J, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:976-82. (Pubitemid 44044779)
17. Lees AJ, Katzenschlager R, Head J, et al. Ten-year follow-up of three different initial treatments in de novo PD: a randomized trial. Neurology. 2001;57:1687-94. (Pubitemid 33055490)
18. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-508.
19. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl. 2006;70:419-26. (Pubitemid 44622232)
20. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-83.
21. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51:604-12.
22. Pålhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200-6. (Pubitemid 43739704)
23. Holford NH, Chan PL, Nutt JG, et al. Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn. 2006;33:281-311. (Pubitemid 44020383)
24. Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Focus on Parkinson's Disease. 2007;19:18-21.